Literature DB >> 222839

Suppression of the in vitro secondary response to syngeneic tumor and of in vivo tumor therapy with immune cells by culture-induced suppressor cells.

P D Greenberg, M Cheever, A Fefer.   

Abstract

Mice with advanced disseminated syngeneic tumor can be successfully treated with a combination of chemotherapy and adoptively transferred syngeneic immune cells. We have previously demonstrated that in vivo primed cells secondarily sensitized in vitro became more effective in tumor therapy, whereas primed cells cultured for 5 days without tumor stimulation became less effective than an equal number of uncultured fresh primed cells. Therefore, we examined stimulated and unstimulated cultures of tumor-primed cells for the presence of culture-induced suppressor cells, and determined whether in vivo tumor therapy with immune cells could be inhibited by concurrent inoculation of immune effector cells and cultured normal spleen cells, which contain culture-induced suppressor cells but are devoid of additional effector cells. The in vitro primary allogeneic response was suppressed by cultured normal spleen cells, or tumor-primed spleen cells previously cultured for 5 days with or without tumor stimulation. In vitro secondary sensitization to syngeneic tumor was suppressed by normal or tumor-primed cells that had previously been cultured for 5 days without stimulation. The majority of this suppression was mediated by T cells in the cultured populations. The efficacy of fresh tumor-primed cells, as well as primed cells secondarily sensitized in vitro, in adoptive chemoimmunotherapy of advanced tumor was diminished by concurrent inoculation of cultured normal cells. The cells mediating suppression of in vivo therapy required previous in vitro culture for induction, and were radiation sensitive.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 222839

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  3 in total

Review 1.  Specific adoptive immunotherapy: experimental basis and future potential.

Authors:  P D Greenberg; M A Cheever; A Fefer
Journal:  Surv Immunol Res       Date:  1982

2.  Prevention of lymph node metastases by adoptive transfer of CD4+ T lymphocytes admixed with irradiated tumor cells.

Authors:  K Yoshida; T Tachibana
Journal:  Cancer Immunol Immunother       Date:  1993-05       Impact factor: 6.968

3.  Suppression of the generation of secondary virus-specific proliferative and cytotoxic T lymphocytes by suppressor cells induced during primary anti-viral sensitization in vitro.

Authors:  G Kreeb; W D Creighton; R M Zinkernagel
Journal:  Immunology       Date:  1981-05       Impact factor: 7.397

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.